⚙AI-generated summary
by qwen3.7-flash, 2026-09-12
ⓘ
This patent discloses CHO cells expressing human LH-RH receptors and screening methods to identify compounds for pharmaceutical compositions treating conditions including endometriosis, prostate cancer, uterine cancer, breast cancer, pituitary tumors, hysteromyoma, precocious puberty, and pregnancy.
One-sentence paraphrase of the abstract; not a substitute for reading it.
No clinical advice. How this works
Abstract
Disclosed are CHO cells which are capable of continued production of human LH-RH receptor proteins, or cell membrane fractions thereof; recombinant human LH-RH receptor proteins or partial peptides thereof; methods for screening compounds which have affinity for an LH-RH receptor by contacting the compound with the CHO cells or the cell membrane fractions thereof, or the recombinant human LH-RH receptor proteins or the partial peptides thereof; kits for screening them; the compounds which have affinity for the LH-RH receptor obtained by methods for the screening or kits for the screening; and pharmaceutical compositions containing the compound, thereby being able to early provide prophylactic or therapeutic compositions, for example, for prostate cancer, uterine cancer, breast cancer, a pituitary tumor, endometriosis, hysteromyoma or precocious puberty. They are also useful as a pregnancy controlling composition such as contraceptive or a menstrual cycle controlling composition.
My notes (saved in your browser only)
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
The paper's references may be in our DB but unresolved to
``paper_id`` (resolution happens at ingest when the cited DOI
matches a row we already have). Run the cross-source citation
reconcile pass to retry.